This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Langeveld, M. Articles by Serlie, M. J. Search for Related Content PubMed PubMed Citation Articles by Langeveld, M. Articles by Serlie, M. J. Related Collections Pediatric Endocrinology Diabetes and Insulin Metabolism

Type I Gaucher Disease, a Glycosphingolipid Storage Disorder, Is Associated with Insulin Resistance

Departments of Endocrinology and Metabolism (M.L., H.P.S., C.E.M.H., M.J.S.), of Medical Biochemistry (K.J.M.G., J.E.M.G., J.M.A.), and of Clinical Chemistry (M.T.A.), Laboratory of Endocrinology and Radiochemistry, Academic Medical Center, 1105AZ Amsterdam, The Netherlands

Address all correspondence and requests for reprints to: M. Langeveld, Academic Medical Center, Department of Endocrinology and Metabolism (F4–247), Meibergdreef 9, 1105AZ Amsterdam, The Netherlands. E-mail: m.langeveld{at}amc.uva.nl.

Context: Complex glycosphingolipids, in majority the ganglioside GM3, surround the insulin receptor in a special membrane compartment (raft) and modulate signaling through this receptor. Increased levels of GM3 in rafts impair insulin signaling, resulting in insulin resistance. Gaucher disease is a lysosomal storage disorder in which impaired breakdown of glucosylceramide leads to its accumulation in macrophages. Secondary to this defect, GM3 concentrations, for which glucosylceramide is the precursor, in plasma and several cell types are elevated.

Objective: We studied the influence of glycosphingolipid storage on whole body glucose and fat metabolism by measuring insulin-mediated (IMGU) and noninsulin-mediated glucose uptake (NIMGU) and suppression of free fatty acids by insulin.

Design and Main Outcome Measures: We studied six Gaucher patients, either naive to treatment or with considerable remaining burden of disease, and six matched healthy control subjects in the basal state, during an euglycemic and a hyperglycemic clamp with somatostatin measuring NIMGU and during an euglycemic hyperinsulinemic clamp measuring IMGU, using stable isotopes.

Results: NIMGU (both during euglycemia and hyperglycemia) did not differ between patients and control subjects. IMGU was lower in Gaucher patients, compared with controls. Suppression of lipolysis by insulin tended to be less effective in Gaucher patients.

Conclusion: Gaucher disease, a lysosomal glycosphingolipid storage disorder, is associated with (peripheral) insulin resistance, possibly through the influence of glycosphingolipids on insulin receptor functioning.